FDAsafety guidance72% confidence
FDA Rare Disease Innovation Hub
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (rare disease) as Genzyme.
Regulatory Analysis
FDA created the Rare Disease Innovation Hub (the Hub) to serve as a point of collaboration and connectivity between CBER and CDER with the goal of ultimately improving outcomes for patients.
Supporting Context
- Therapeutic area
- Genetic Disorders · Pompe Disease
- Sub-indication
- Rare Disease
Related signal: Genzyme Launches Global Registry for Pompe Disease to Enhance Patient Care and Research